Amgen (AMGN) : First Premier Bank added new position in Amgen during the most recent quarter end. The investment management firm now holds 3,493 shares of Amgen which is valued at $573,865 , the company said in a statement filed on Oct 13, 2016 with the SEC.Amgen makes up approximately 0.44% of First Premier Bank’s portfolio.
Other Hedge Funds, Including , Legacy Private Trust added AMGN to its portfolio by purchasing 13,323 company shares during the most recent quarter which is valued at $2,189,235. Amgen makes up approx 0.30% of Legacy Private Trust’s portfolio.Creative Planning boosted its stake in AMGN in the latest quarter, The investment management firm added 8,019 additional shares and now holds a total of 75,194 shares of Amgen which is valued at $12,355,878. Amgen makes up approx 0.08% of Creative Planning’s portfolio. Stillwater Capital Advisors added AMGN to its portfolio by purchasing 1,215 company shares during the most recent quarter which is valued at $204,497. Amgen makes up approx 0.06% of Stillwater Capital Advisors’s portfolio.
Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.